When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Breast cancer management - Wikipedia

   en.wikipedia.org/wiki/Breast_cancer_management

   Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.

3. Targeted therapy - Wikipedia

   en.wikipedia.org/wiki/Targeted_therapy

   There are targeted therapies for lung cancer, colorectal cancer, head and neck cancer, breast cancer, multiple myeloma, lymphoma, prostate cancer, melanoma and other cancers. [ 1 ] [ 4 ] [ 5 ] Biomarkers are usually required to aid the selection of patients who will likely respond to a given targeted therapy.

4. Trastuzumab deruxtecan - Wikipedia

   en.wikipedia.org/wiki/Trastuzumab_deruxtecan

   Trastuzumab deruxtecan is indicated for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting and for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal ...

5. Trastuzumab - Wikipedia

   en.wikipedia.org/wiki/Trastuzumab

   The optimal duration of add-on trastuzumab treatment after surgery for early breast cancer is unknown. One year of treatment is generally accepted based on clinical trial evidence that demonstrated the superiority of one-year treatment over none. [47] [48] However, a small Finnish trial also showed similar improvement with nine weeks of ...

6. Sacituzumab govitecan - Wikipedia

   en.wikipedia.org/wiki/Sacituzumab_govitecan

   Sacituzumab govitecan is indicated for the treatment of adults with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease; [11] people with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease; [14] and for people ...

7. Pertuzumab - Wikipedia

   en.wikipedia.org/wiki/Pertuzumab

   Pertuzumab, sold under the brand name Perjeta, is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer. [4] Side effects in more than half the people taking it include ...